Mifepristone Therapy in Symptomatic Leiomyomata Using a Variable Dose Pattern with a Favourable Outcome

Area of Science:

• Reproductive endocrinology and women's health.
• Pharmacological management of gynecological conditions.

Background:

• Symptomatic uterine leiomyomata significantly impact women's health during reproductive years.
• Uterine leiomyomata, commonly known as fibroids, are benign tumors that can cause heavy bleeding, pain, and infertility.

Purpose of the Study:

• To evaluate the efficacy of mifepristone, a progesterone antagonist, in alleviating leiomyoma-related symptoms.
• To assess the potential of mifepristone as a conservative treatment for leiomyomata in perimenopausal women.

Main Methods:

• A study involving 10 women (7 perimenopausal, 3 premenopausal) treated with mifepristone over 9 months to 1 year.
• Treatment involved a stepwise declining dose of mifepristone, starting at 25 mg, with regular monitoring of myoma size, bleeding, and other health indicators.

Main Results:

• Mifepristone demonstrated significant reduction in leiomyoma size and symptom amelioration in both premenopausal and perimenopausal groups.
• While symptoms recurred in premenopausal women after drug cessation, 6 out of 7 perimenopausal women experienced complete symptom abatement and a smoother menopausal transition.

Conclusions:

• Mifepristone shows significant promise for the conservative management of uterine leiomyomata, particularly in women aged 47 and older.
• The drug successfully averted hysterectomy in all studied perimenopausal women, highlighting its potential in preserving reproductive health.